Spiral
Work at Spiral?
About Spiral
Spiral is a small, high-caliber team based in New York and London. The company has raised funding from venture capital firms, including a Seed round led by Amplify Partners and a Series A led by General Catalyst last year, and it has a runway of 7+ years to tackle bold ideas. Spiral was founded by Will Manning (CEO), Robert (President), and Nick Gates (CTO), who all have experience at Palantir; Manning has 9+ years at Palantir, Robert 8+ years, and Gates 6 years at Palantir and 2 years at Citadel.
Company at a glance
Location
Culture & values
The company is a small, high-caliber team.
The company has teams located in New York and London.
The company aims to tackle bold ideas.
Life at Spiral
Frequently asked questions
Companies similar to Spiral
Building brands, Creating new relationships, Adding value to our clients
Zaimler focuses on a platform shift in data infrastructure, moving beyond traditional databases to AI-based, question-driven data interaction. It is building a platform to revolutionize data context, enabling AI agents to retrieve, understand and utilize information effectively. The company operates with a lean team of 12 and benefits from deep expertise and proven founder pedigree. Zaimler has significant traction and is signing 7-figure contracts.
Aira is an AI platform designed for procedural specialties that serves as the payer intelligence layer for medical device companies and surgical practices. The company automates critical back-office workflows while handling the full payer compliance lifecycle, including benefits verification, medical necessity determinations, prior authorization, and appeals management. By functioning as the intelligence layer powering market access teams, Aira helps healthcare providers and device manufacturers navigate the complexity of reimbursement processes to increase patient access to needed procedures. The platform addresses a key pain point in healthcare operations by streamlining the administrative burden that often delays care and complicates market entry for medical innovations.


